Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors

Completed

• Conditions: Breast Cancer; Long-Term Survivors
• Interventions: Behavioral: Mini-Mental State Exam and Blood Draw

• Registration Number: NCT00496613
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to learn more about how chemotherapy affects an individual's thinking abilities (cognition). Some research has shown that chemotherapy can cause changes in cognition in breast cancer survivors. However, it is not clear why this change occurs. In this study, the investigators will look to see if damage to DNA is related to these changes in cognition. Specifically, the investigators want to see 1) if women who have been treated with chemotherapy have more DNA damage than healthy women; and 2) if DNA damage is related to cognitive problems in breast cancer survivors and healthy women.

Detailed Description

The primary objective of this proposal is to obtain preliminary data regarding the association between DNA damage and cognitive functioning in breast cancer survivors. Specifically, we predict that:

1. Breast cancer survivors treated with chemotherapy and hormonal therapy will have higher levels of DNA damage as measured by the Comet assay as compared to age and education matched survivors treated with hormonal therapy only and healthy controls.

2. Survivors who meet criteria for cognitive impairment will have higher levels of DNA damage as compared to cancer survivors who do not meet criteria for cognitive impairment and healthy controls.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2007-06
• Study First Submitted: 2007-07-03
• Study First Submitted QC: 2007-07-03
• Study First Posted: 2007-07-04
• Status Verified: 2022-04
• Primary Completion: 2022-04-18
• Study Completion: 2022-04-18
• Last Update Submitted: 2022-04-20
• Last Update Posted: 2022-04-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

• Breast cancer survivors (Stage I-III) 2-6 years post all cancer treatments, but currently receiving hormone therapy.
• History of treatment with chemotherapy and/or hormonal therapy, or hormone therapy only.
• No evidence of active/recurrent disease.
• Less than 70 years old at time of recruitment.
• Post-menopausal prior to initial treatment.
• In the judgment of the consenting professional, is able to provide informed consent.
• Patient is able to understand English, through verbal and written communication.

Read More

Exclusion Criteria

• Recurrence of breast cancer or diagnosis of another cancer except basal cell carcinoma.
• Exposure to chemotherapy or radiation therapy for any medical condition unrelated to breast cancer.
• Neurobehavioral risk factors including history of neurological disorder, or moderate to severe head trauma (loss of consciousness > 60 min or evidence of structural brain changes on imaging).
• Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.
• Self-reported sleep disorders that could influence cognitive functioning including sleep apnea and chronic fatigue syndrome.
• Self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia.
• Disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia.
• Male.

Healthy Control Inclusion Criteria:

• Have had no diagnosis of cancer except basal cell carcinoma.
• Less than 70 years old at time of recruitment.
• Post-menopausal.
• In the judgment of the consenting professional, is able to provide informed consent.
• Patient is able to understand English, through verbal and written communication

Healthy Control Exclusion Criteria:

• Exposure to chemotherapy or radiation therapy for any medical condition.
• Neurobehavioral risk factors including history of neurological disorder, or moderate to severe head trauma (loss of consciousness > 60 min or evidence of structural brain changes on imaging).
• Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis etc.
• Self-reported sleep disorders that could influence cognitive functioning including sleep apnea and chronic fatigue syndrome.
• Self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia.
• Male.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
3	Mini-Mental State Exam and Blood Draw	Healthy women matched on age and education
1	Mini-Mental State Exam and Blood Draw	Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with a combination of chemotherapy and hormonal therapy, matched on age and education
2	Mini-Mental State Exam and Blood Draw	Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with hormonal therapy only matched on age and education

Primary Outcome Measures

Name	Time	Method
The primary goal of this preliminary study is to examine the relationship between DNA damage and chemotherapy-induced cognitive changes in breast cancer survivors.	2 years

Trial Locations

Locations (3)

Memorial Sloan Kettering Cancer Center at Commack; 🇺🇸 Commack, New York, United States

Memorial Sloan Kettering Cancer Center at Mercy Medical Center; 🇺🇸 Rockville Centre, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States